A Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Q-122 for the Treatment of Vasomotor Symptoms in Female Breast Cancer Patients/Survivors Taking Tamoxifen or an Aromatase Inhibitor
Phase of Trial: Phase II
Latest Information Update: 16 Nov 2018
At a glance
- Drugs Q 122 (Primary)
- Indications Hot flashes
- Focus Proof of concept; Therapeutic Use
- Sponsors QUE Oncology
- 05 Nov 2018 Status changed from not yet recruiting to recruiting.
- 19 Oct 2018 Planned End Date changed from 1 Jul 2019 to 1 Aug 2019.
- 19 Oct 2018 Planned primary completion date changed from 1 Feb 2019 to 1 Jul 2019.